Ethnopharmacology in Latin America, 2nd Edition

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: closed (20 June 2026) | Viewed by 690

Editor

Special Issue Information

Dear Colleagues,

Latin America is a multicultural region that encompasses 43 countries, and it has formed the settlement of many pre-Hispanic civilizations, whose knowledge and culture still remain. This region is the home of over 50 million indigenous people belonging to 400 different ethnic groups. Their ancient knowledge has been incorporated into many pharmacopeias from this region. Latin America has many endemic medicinal plants. However, this region is facing a loss of biodiversity. Migration to rural areas is resulting in the loss of ethnomedicinal information. In Latin America, the use of medicinal plants for primary healthcare is a common practice among the general population due to the lack of/insufficient medical attention and the lack of economic resources. Many of these medicinal plants have yet to be studied for their toxicology, pharmacology, and chemistry. This Special Issue will be focused on the following topics: (i) ethnobotanical studies using quantitative tools, (ii) survey-based studies about self-medication/use of herbal products, (iii) preclinical and clinical studies with plant extracts and their active compounds, (iv) analytical procedures for the standardization of plant extracts, and (v) legislation and regulation of herbal products. The journal Pharmaceuticals invites experts to contribute to this Special Issue with reviews and original research articles focusing on the pharmacology, toxicology, analytical chemistry, pharmacy, and ethnobotany of medicinal plants endemic to Latin America.

Dr. Angel Josabad Alonso-Castro
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Latin America
  • preclinical
  • clinical
  • ethnobotany
  • pharmacology
  • chemical standardization
  • herbal products

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 1405 KB  
Article
Bioactive Potential of Agave tequilana Dry Juice Extract: Chemical Profiling, Antinociceptive Effects, and Synergistic Modulation with Diclofenac in the Formalin Test
by Reinner David Higuera-Quira, Juan Ramón Zapata-Morales, Josué Vidal Espinosa-Juárez, Elena Franco-Robles, Nereida Violeta Vega-Cabrera, Fidel Avila-Ramos, Clara Alba-Betancourt, Citlaly Natali de la Torre-Sosa and Osmar Antonio Jaramillo-Morales
Pharmaceuticals 2026, 19(6), 863; https://doi.org/10.3390/ph19060863 - 29 May 2026
Viewed by 275
Abstract
Background: Safer analgesic strategies are needed to reduce the adverse effects associated with prolonged use of nonsteroidal anti-inflammatory drugs. The dry juice extract of Agave tequilana (ESPA), a chemically complex matrix with anti-inflammatory potential, may represent a promising adjuvant for modulating inflammatory [...] Read more.
Background: Safer analgesic strategies are needed to reduce the adverse effects associated with prolonged use of nonsteroidal anti-inflammatory drugs. The dry juice extract of Agave tequilana (ESPA), a chemically complex matrix with anti-inflammatory potential, may represent a promising adjuvant for modulating inflammatory pain. Objective: This study evaluated the antinociceptive activity of ESPA and its pharmacological interaction with diclofenac in the formalin test. Methods: BALB/c mice received ESPA or diclofenac orally 30 min before pain induction, and nociceptive behavior was quantified by counting paw flinches during the neurogenic and inflammatory phases. The GC–MS-detectable fraction of ESPA was chemically characterized, while the pharmacokinetic and bioactivity profiles of selected compounds were explored in silico using SwissADME and PASSonline. Molecular docking with COX-1 and COX-2 was performed using AutoDock Vina. Acute toxicity was evaluated according to OECD Guideline 423, and the ESPA–diclofenac interaction was examined using isobolographic analysis. Results: ESPA produced significant antinociceptive effects during the inflammatory phase. Although diclofenac exhibited greater potency, ESPA showed consistent efficacy in reducing inflammatory nociceptive behavior. GC–MS analysis identified several compounds within the detectable volatile/lipophilic fraction, including n-hexadecanoic, octadecanoic, and oleic acids. In silico evaluations suggested favorable predicted oral absorption and potential bioactivities related to inflammatory mediator regulation. Docking studies showed moderate predicted affinities for COX-1 and COX-2, lower than those observed for diclofenac. Isobolographic analysis demonstrated a synergistic interaction between ESPA and diclofenac, allowing dose reduction while maintaining antinociceptive efficacy. Acute toxicity testing indicated no signs of toxicity at the evaluated dose. Conclusions: These findings suggest that ESPA may act as a potential adjuvant in diclofenac-based analgesic strategies for inflammatory pain; however, further studies are required to clarify the active constituents and underlying mechanisms. Full article
(This article belongs to the Special Issue Ethnopharmacology in Latin America, 2nd Edition)
Show Figures

Graphical abstract

Back to TopTop